Is it time to revisit follicle-stimulating hormone therapy in men with azoospermia?


Like Comment
Related Content

VOLUME 115, ISSUE 3, P576-577, MARCH 01, 2021


Richard J. Fantus, M.D., Joshua A. Halpern, M.D., M.P.H., Robert E. Brannigan, M.D.


Although follicle-stimulating hormone (FSH) is necessary for male fertility, its pharmacologic use in infertile men has remained limited. Outside the use of recombinant or purified FSH therapy in hypogonadotropic hypogonadism, the use of therapeutic FSH remains controversial (1, 2). Several meta-analyses have attempted to investigate the use of FSH in different stages of male reproduction, but study heterogeneity often has been a limitation (2). Despite this heterogeneity, FSH treatment in these meta-analyses has shown improvements in semen parameters and live-birth rates among men with normogonadotropic idiopathic oligospermia, which has led to region-specific consensus statements (2). While this gives hope for the potential use of FSH, the therapeutic use of FSH in azoospermic men remains poorly investigated (2).

Read the full text here. 

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.